Pfizer's second-quarter revenue and adjusted earnings per share both exceeded analyst estimates, showing a growth from the previous year. Pfizer raised its full-year revenue and adjusted EPS guidance, reflecting increased expectations from earlier projections. Sales of the company's COVID antiviral pill, Paxlovid, increased year over year, beating estimates. Demand has increased in international markets. The company is focusing on cancer treatments following its acquisition of Seagen last year.